Skip to main content

Research Article Details

Peer-Reviewed Open Access Publication · ISSN: 2321-8681 · CC-BY 4.0 International

Open Access ISSN: 2321-8681 Volume-8, Issue-1 (Jan-June) 2021

Bioinformatics study of the potential of JAK/STAT pathway inhibition as a new treatment strategy to control cytokine release syndrome in COVID-19

Authors: Bahareh Farasati Far, Ali Aghajani Shahrivar, Hazha Omar Othman, Mehdi Shafiee Ardestani, Hamidreza Pazoki Toroudi India
Correspondence: pazoki1970@gmail.com
Download Full PDF Cite Article Back to Archives

Abstract

COVID-19, a pandemic affecting virus, which is caused by the current SARS-CoV2 coronavirus. The present research is performed on anti-virus and immune-modulating therapies. Cytokine storms are the toxic drivers and mortality caused by various human viral infections. In addition, the intensity was linked to an elevated risk of acute respiratory failure, myocardial injury, and mortality in SARS-CoV-2-infected patients. The Janus kinase (JAK) therapeutic inhibitor class showed significant clinical benefits in anti-inflammatory and anti-viral effects. Among them, filgotinib has been approved as an active JAK inhibitor by decreasing biomarkers with main immune reaction functions and markers supporting matrix-degradation, angiogenesis, leukocyte adhesion, and recruitment in both research trials. In this study, we tried to get an insight into the choice of this drug in controlling the jack to treat COVID-19 using drug design methods.

Journal Research and Reviews in Biotechnology and Biosciences
Peer Review Double-Blind Peer Reviewed
Publication Year 2021
Volume Volume-8, Issue-1 (Jan-June)
DOI http://doi.org/10.5281/zenodo.5118342
Cite this Article

Select a citation style to copy or import directly into your reference manager:

Bahareh Farasati Far, Ali Aghajani Shahrivar, Hazha Omar Othman, Mehdi Shafiee Ardestani, Hamidreza Pazoki Toroudi (2021). Bioinformatics study of the potential of JAK/STAT pathway inhibition as a new treatment strategy to control cytokine release syndrome in COVID-19. Research and Reviews in Biotechnology and Biosciences, Volume-8, Issue-1 (Jan-June). http://doi.org/10.5281/zenodo.5118342
Bahareh Farasati Far, Ali Aghajani Shahrivar, Hazha Omar Othman, Mehdi Shafiee Ardestani, Hamidreza Pazoki Toroudi, 2021. Bioinformatics study of the potential of JAK/STAT pathway inhibition as a new treatment strategy to control cytokine release syndrome in COVID-19. Research and Reviews in Biotechnology and Biosciences, Volume-8, Issue-1 (Jan-June).
Bahareh Farasati Far, Ali Aghajani Shahrivar, Hazha Omar Othman, Mehdi Shafiee Ardestani, Hamidreza Pazoki Toroudi. "Bioinformatics study of the potential of JAK/STAT pathway inhibition as a new treatment strategy to control cytokine release syndrome in COVID-19." Research and Reviews in Biotechnology and Biosciences Volume-8, Issue-1 (Jan-June) (2021).
@article{rrbb_170_BaharehFa, title = {{Bioinformatics study of the potential of JAK/STAT pathway inhibition as a new treatment strategy to control cytokine release syndrome in COVID-19}}, author = {Bahareh Farasati Far, Ali Aghajani Shahrivar, Hazha Omar Othman, Mehdi Shafiee Ardestani, Hamidreza Pazoki Toroudi}, journal = {Research and Reviews in Biotechnology and Biosciences}, issn = {2321-8681}, year = {2021}, volume = {Volume-8, Issue-1 (Jan-June)}, doi = {http://doi.org/10.5281/zenodo.5118342} }
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source.